Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Nycomed to Market Roche Osteoporosis Drug in China and Asia-Pacific

publication date: Jun 15, 2011
Nycomed, the Swiss biopharma, will market a Roche osteoporosis treatment, Bonviva, in China and other Asia Pacific markets. Boniva, a bisphosphonate, will be added to Nycomed’s existing portfolio of osteoporosis products. Nycomed, the 28th largest biopharma in the world, generates the highest proportion of its revenues from developing countries of any large or medium-sized global pharma – an unusual metric – though China is not one of its top five markets. More details....

Stock Symbol: (VS: ROG)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital